A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan

Active, not recruitingOBSERVATIONAL

Enrollment

525

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

June 1, 2026

Conditions

Non-Small Cell Lung Cancer

Trial Locations (1)

Local Institution, Minato-ku